News

15
Sep

Positron Announces Timeline for Becoming Current with its OTC Reporting & Disclosures 

Niagara Falls, NY – September 14, 2021 (GLOBE NEWSWIRE) -- Positron Corp (“Positron” or the “Company”) (OTC: POSC) is pleased to announce that Positron has received full OTCIQ access for its filing and approval process with OTC... Read More

15
Jul

Positron Retains Healthcare Advisor I-Square Ventures to Implement Strategy and Expand Market Share

Niagara Falls, NY – July 15, 2021 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC) is pleased to announce today that it has retained the services of I- Square Ventures (“I-Square”)... Read More

28
Dec

By performing myocardial perfusion imaging (MPI) with cardiac FDG-PET before revascularization, clinicians can better assess the benefits of that procedure and predict near-term outcomes for patients with coronary artery disease and left ventricular dysfunction, according to a study presented on Sunday at RSNA 2018.... Read More

13
Nov

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the American Society of Nuclear Cardiology (ASNC) submitted a letter to BlueCross BlueShield (BCBS) of Tennessee urging an expansion of cardiac PET coverage.

 

Full Text

13
Nov

GE Healthcare and Lantheus Medical Imaging have launched a second phase III clinical trial for Lantheus' flurpiridaz F-18 investigational PET radiopharmaceutical.

Full Text

13
Nov

Florbetapir-PET scans show that midlife adults with two or more vascular risk factors are significantly more likely to have greater levels of amyloid deposits in their brains later in life than peers with no such risk factors, according to a study published April 11 in the Journal of the American Medical... Read More